Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRL_RI vs MabThera in Low Tumor Burden Follicular Lymphoma
NCT03976102Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- May 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), sponsored by Dr. Reddy's Laboratories. Started May 2019; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03976102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976102.